Experience with freeze-dried PGLA/HA/rhBMP-2 as a bone graft substitute.
We investigated bone induction by recombinant human bone morphogenetic protein-2 in rodents. The purpose of this study was to evaluate the osteoinductive potential of a resorbable bone substitute fabricated from freeze-dried poly(glycolic acid-co-lactic acid) (PGLA) mixed with hydroxyapatite particles incorporated with bone morphogenetic protein-2 in skull defects of rats (FD-PGLA/HA/rhBMP-2). The FD-PGLA/HA/rhBMP-2 composite or as a control, the FD-PGLA/HA by itself were implanted in skull defects (psi 8 mm) of rats. The samples were harvested at 2 or 4 weeks postoperatively and were studied radiographically and histologically. Four weeks after implantation, the FD-PGLA/HA/rhBMP-2 discs were completely replaced by newly-formed bone possessing bone marrow. In contrast, the defects implanted with FD-PGLA/HA were filled only with fibrous connective tissue. The results suggest that the FD-PGLA/HA/rhBMP-2 composite could be an optimum bone substitute with osteoinductive potential and could function as an alternative bone graft material for autogenous bone in humans.
Miki
T
T
Department of Oral Restitution, Graduate School, Tokyo Medical and Dental University, Japan.
Masaka
K
K
Imai
Y
Y
Enomoto
S
S
D020341:Absorbable Implants; D000704:Analysis of Variance; D000818:Animals; D001672:Biocompatible Materials / Q000627:therapeutic use*; D001847:Bone Diseases / Q000000981:diagnostic imaging / Q000473:pathology / Q000601:surgery; D001853:Bone Marrow / Q000000981:diagnostic imaging / Q000473:pathology; D055396:Bone Morphogenetic Protein 2; D019485:Bone Morphogenetic Proteins / Q000627:therapeutic use*; D018786:Bone Substitutes / Q000627:therapeutic use*; D016025:Bone Transplantation; D003238:Connective Tissue / Q000000981:diagnostic imaging / Q000473:pathology; D017886:Durapatite / Q000627:therapeutic use*; D005500:Follow-Up Studies; D005612:Freeze Drying; D006801:Humans; D019344:Lactic Acid / Q000627:therapeutic use*; D010012:Osteogenesis / Q000187:drug effects; D011100:Polyglycolic Acid / Q000627:therapeutic use*; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011108:Polymers / Q000627:therapeutic use*; D011859:Radiography; D051381:Rats; D011994:Recombinant Proteins; D012886:Skull / Q000000981:diagnostic imaging / Q000473:pathology / Q000601:surgery; D013223:Statistics as Topic; D016212:Transforming Growth Factor beta / Q000627:therapeutic use*
C525718:BMP2 protein, human; D001672:Biocompatible Materials; C525720:Bmp2 protein, rat; D055396:Bone Morphogenetic Protein 2; D019485:Bone Morphogenetic Proteins; D018786:Bone Substitutes; D011108:Polymers; D011994:Recombinant Proteins; D016212:Transforming Growth Factor beta; C499469:recombinant human bone morphogenetic protein-2; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011100:Polyglycolic Acid; D019344:Lactic Acid; D017886:Durapatite